WHA28.66  Prophylactic  and  therapeutic  substances 
The Twenty-eighth  World  Health  Assembly, 
Having  considered  the report  of the Director-General  on prophylactic  and  therapeutic  substances  ；2 
Recognizing  the  importance  of further  development  of international  standards  and  requirements  for 
prophylactic  and  therapeutic  substances; 
Convinced  of the necessity  of developing  drug  policies  linking  drug  research,  production  and  distribution 
with  the real  health  needs, 
1. THANKS  the Director-General  for his comprehensive  report; 
2. URGES  governments  and  professional  bodies  to ensure  that  the  health  personnel  and  the  public  are 
adequately  educated  and  kept  informed  as to the proper  use  of prophylactic  and  therapeutic  substances;  and 
3. REQUESTS  the Director-General  : 
(1) to continue  to develop  activities  related  to the establishment  and  revision  of international  standards, 
requirements  and  guidelines  for prophylactic  and  therapeutic  substances  in consultation,  as appropriate, 
with  relevant  governmental  and  nongovernmental  organizations  in official  relations  with  WHO; 
(2) to develop  means  by which  the Organization  can  be of greater  direct  assistance  to Member  States  in: 
(a) the  implementation  of national  programmes  in research,  regulatory  control,  management  and 
monitoring  of drugs  and,  in so doing,  also  in the formulation  of national  drug  policies; 
(b) advising  on the selection  and  procurement,  at reasonable  cost,  of essential  drugs  of established 
quality  corresponding  to their  national  health  needs  ； 
(c) the  education  and  training  of scientific  and  technical  manpower  for  research,  production, 
evaluation,  control  and  management  of prophylactic  and  therapeutic  substances  ； 
(3) to study  ways  and  means  of optimizing  inputs  and  outputs  of the international  system  for drug 
monitoring  so that  it will  be useful  for both  developed  and  developing  countries; 
(4) to disseminate  to Member  States  evaluated  information  on drugs;  and 
(5) to report  on the above  matters  to the Executive  Board  and  a future  World  Health  Assembly. 
Handb.  Res.,  Vol.  II, 1.10.1;  1.10.4 Thirteenth  plenary  meeting,  29 May  1975 
(Committee  B,  seventh  report) 
